Abstract
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder presenting with low platelet count <100 × 109/L. The condition affects both adults and children. Thrombopoietin receptor agonists (TPO-RAs) are second-line of therapy that includes Romiplostim and Eltrombopag, which stimulate the production of normally functioning platelets. Although the biological effect of these drugs is well established, there has not been a meta-analysis in children. To estimate the efficacy and safety of Romiplostim and Eltrombopag, we performed a systematic review and meta-analysis in children with chronic ITP. Systematic literature search was conducted in the following database: PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL). Review Manager 5.3 for Windows was used to analyze the data. Five randomized controlled trials with total of 261 pediatric patients from 1-17 years of age were included. The efficacy and safety analysis showed TPO-RA groups were superior over placebo, and there was no difference in adverse event occurrence between TPO-RA (Romiplostim and Eltrombopag) and placebo groups. The efficacy and safety of Eltrombopag did not differ significantly from those of Romiplostim. Both drugs were effective i...Continue Reading
References
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Jan 15, 1999·Epidemiology·S GreenlandJ M Robins
Jun 24, 2003·Statistics in Medicine·Norma TerrinIngram Olkin
Dec 14, 2004·Clinical Pharmacology and Therapeutics·Bing WangJohn T Sullivan
Feb 15, 2011·Annals of Hematology·Mohsen Saleh ElalfyKhadiga Yehia Eltonbary
Apr 20, 2011·Blood·James B BusselSusie Jun
Sep 2, 2011·Haematologica·Thomas KühneUNKNOWN Intercontinental Cooperative ITP Study Group
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Mar 2, 2012·Pediatric Hematology and Oncology·Vicente Escudero VilaplanaMaría Sanjuro Sáez
Apr 5, 2012·Platelets·Galila M MokhtarNayera H K El Sherif
Oct 18, 2012·Journal of Pediatric Hematology/oncology·John A D'OrazioNina Farhoudi
Oct 25, 2013·British Journal of Haematology·Marlène PasquetUNKNOWN Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE)
Jan 4, 2015·BMJ : British Medical Journal·Larissa ShamseerUNKNOWN PRISMA-P Group
Aug 2, 2015·Lancet·John D GraingerChristine K Bailey
Sep 1, 2015·Frontiers in Pediatrics·Angelica Maria Garzon, William Beau Mitchell
Sep 5, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Thi-Thanh Loan NguyenGuillaume Moulis
Dec 22, 2015·The Lancet. Haematology·James B BusselKalpana K Bakshi
Apr 23, 2016·Lancet·Michael D TarantinoMelissa Eisen
May 3, 2016·Pediatric Blood & Cancer·Cindy NeunertUNKNOWN Pediatric ITP Consortium of North America (ICON)
Aug 31, 2016·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Ahmed Saber ElgebalyAhmed Menshawy
Dec 20, 2016·Scientific Reports·Li WangChun-Ji Gao
Citations
Jul 12, 2019·Drugs·Bruno FattizzoWilma Barcellini
Jun 27, 2019·Blood Advances·Cindy E Neunert, Melissa J Rose
Mar 18, 2020·Frontiers in Medicine·Paola GiordanoGiovanni Carlo Del Vecchio
Dec 29, 2020·Hematology·Mo ChenLu-Hong Xu
Mar 16, 2021·Pediatric Blood & Cancer·Lingling FuRunhui Wu
Apr 21, 2021·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Hafiz Abdul Waqas AhmedKai Sun
Aug 29, 2021·BMJ Open·Kristin A ShimanoCindy Neunert
Oct 5, 2021·Blood Advances·Xiaoling ChengRunhui Wu
Dec 29, 2021·Pediatric Blood & Cancer·Nawal MerjanehBrian Turpin
Jun 1, 2020·Endocrine, Metabolic & Immune Disorders Drug Targets·Giuseppe LassandroPaola Giordano